Shashank Sinha, MD
Cardiovascular Disease · Falls Church, VANPI 1588808075
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Abbott at 42.3% of the total.
Across 81 payments — averaging $150.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$5K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$3K
- Abiomed$2K
- Getinge USA Sales, LLC$1K
- Cvrx, Inc.$249
- Impulse Dynamics (USA) Inc.$181
- plus $339 from 6 others
Across 10 payments — averaging $30,629 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$221K
- Procyrion, Inc.$85K
What the payments were for
- Speaking & faculty fees$5,50045%
- Travel & lodging$1,62213%
- Food & beverage$5,09842%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 48 | $5,173 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $3,200 |
| Abiomed | 19 | $1,830 |
| Getinge USA Sales, LLC | 1 | $1,250 |
| Cvrx, Inc. | 3 | $249 |
| Impulse Dynamics (USA) Inc. | 1 | $181 |
| Boston Scientific | 1 | $117 |
| Actelion Pharmaceuticals US, Inc. | 1 | $106 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $43 |
| Novo Nordisk | 1 | $30 |
| Pfizer | 1 | $22 |
| United Therapeutics Corporation | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$3,200
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$2,909
- Impella$1,438
- CARDIOSAVE RESCUE$1,250
- CardioMEMS HF System$942
- OPTIMIZER$361
- CARDIOMEMS$164
- Barostim Neo System$161
- HeartMate Touch$137
- GENERAL - THERAPIES$117
- MitraClip$114
- UPTRAVI$106
- OPSUMIT$106
How this compares
$12,220 in reported general payments places this provider in the 85th percentile of 548 cardiovascular disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 11 | $229,049 |
| EntrestoSacubitril/Valsartan | 62 | $74,870 |
| FarxigaDapagliflozin Propanediol | 20 | $32,998 |
| JardianceEmpagliflozin | 23 | $23,248 |
| Bumetanide | 12 | $779 |
| Metoprolol Succinate | 21 | $667 |
| Spironolactone | 45 | $519 |
| Carvedilol | 32 | $203 |
| Furosemide | 17 | $114 |
| Atorvastatin Calcium | 11 | $109 |
| Warfarin Sodium | 17 | $49 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax | $22 | $229,04911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 548 cardiovascular disease providers in Virginia.
Other cardiovascular disease in Falls Church
- Alexander TruesdellFalls Church$167K
- Christopher OconnorFalls Church$161K
- Joseph KreppFalls Church$74K
- Behnam TehraniFalls Church$58K
- Mitchell PsotkaFalls Church$35K
- Tariq HaddadFalls Church$18K
- Leonard IlkhanoffFalls Church$14K
- George VetrovecRichmond$2.3M
- Hamid TaheriManassas$501K
- Cyrus HadadiNorfolk$360K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.